Cover Image

Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy

Stephen Kinsey-Trotman, Zumin Shi, Beverley Fosh
  • Zumin Shi
    The University of Adelaide, Adelaide, Australia
  • Beverley Fosh
    Modbury Hospital, Modbury, Australia

Abstract

This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Meta-analysis of three studies showed a relative risk of 0.69 (95% confidence interval, 0.60-0.79, P<0.05) for breast malignancies with tamoxifen treatment in a mixed radiotherapy treatment/naïve cohort. Subgroup analysis of DCIS populations in multiple studies showed a trend to benefit with aromatase inhibitor treatment.

Keywords

Ductal carcinoma in situ; tamoxifen; aromatase inhibitor; breast cancer; hormonal; adjuvant.

Full Text:

PDF
HTML
Submitted: 2016-07-18 05:26:33
Published: 2016-12-07 14:11:01
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
634

Views:
PDF
255
HTML
320

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Stephen Kinsey-Trotman, Zumin Shi, Beverley Fosh

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185